2020-2027 Analysis and Review Warfarin Market

Warfarin Market

Warfarin Market by Clinical Application (Atrial Fibrillation, DVT/PE and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

27-07-2020 REP-HC-5145 40 Tables 110 pages Format

The warfarin market was valued at USD 2,278.6 Mn by 2019. Significant increase in the number of people suffering from atrial fibrillation worldwide. Effective implementation of treatment guidelines pertaining to the management of DVT/PE further accentuates the warfarin market growth.

Warfarin Market

Warfarin is classified as an anticoagulant which is used to prevent the formation of blood clot and migraine. It needs to be taken under medical supervision as the drug has the capacity to cross the placental barrier during pregnancy which can eventually result in preterm birth, spontaneous abortion, artery calcification, and osteoporosis. It is a vitamin K antagonist that inhibits its production by the vitamin K epoxide reductase.

The major segments related to the warfarin market are: 

By Clinical Application (2017–2027; US$ Mn)

Atrial Fibrillation

DVT/PE

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global warfarin market
  • The overall segmentation of the warfarin market, by clinical application, distribution channel, and geography is minutely studied. Atrial fibrillation and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Growing incidence of cardiac complications worldwide
  • Effective implementation of the treatment guidelines pertaining to the management of deep vein thrombosis and pulmonary embolism together accentuates the market growth

Report gist?

  • The study of the global warfarin market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of warfarin due to the  rising prevalence of cardiac complications worldwide
  • The report will benefit cardiologist prescribing warfarin for the treatment of deep vein thrombosis and pulmonary embolism across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to warfarin market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Atrial fibrillation is currently dominating the clinical application segment for the warfarin market. As per the latest information provided by the National Institute of Health (NIH), approximately 0.5% of the global population is suffering from atrial fibrillation. The further clinical analysis provides the factors responsible for the occurrence of atrial fibrillation such as congenital heart defects, coronary artery diseases, high intake of caffeine, tobacco, alcohol, etc. DVT/PE will be highlighting comfortable market growth in the near future on account of the growing prevalence rate in the elderly population worldwide. According to the recent information provided by the International Society on Thrombosis and Haemostasis (ISTH), annually 10 million new cases are reported worldwide to be suffering from venous thromboembolism. The clinical manifestations associated with venous thromboembolism are shortness of breath, chest pain swelling of foot and ankles, pain and tenderness in the calf region, lightheadedness, etc.

Hospital pharmacy is presently leading the distribution channel segment for the warfarin market. The drug toxicity associated with the warfarin overdose makes it mandatory for its precise compounding under the supervision of a hospital pharmacist. Retail pharmacy is expected to garner impressive market performance during the forecast period owing to the availability of affordable essential medicines due to government subsidy and its capacity to provide medicinal requirements to households residing in remote locations.

North America is representing the largest market share in the regional segment for the warfarin market. The rising prevalence of cardiac diseases primarily drives the warfarin market growth in the region. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), it is estimated that by 2030 the number of individuals suffering from atrial fibrillation will be 12.1 million in the United States. The existence of well-developed healthcare infrastructure and favorable reimbursement scenario associated with the use of warfarin drug formulation together propels the market growth in the region. Europe is considered as the second-largest regional segment for warfarin market on account of the growing incidence of deep vein thrombosis in the elderly patients in the region. Additionally, the nurturing regulatory environment provided by the European Medical Agency (EMA), regarding the sale and distribution of warfarin in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the warfarin market owing to the effective implementation of treatment guidelines regarding cardiovascular diseases by the local healthcare agencies and the flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.